At the beginning of this year, I laid out a basic objective for Endpoints News as we headed to our 5th anniversary. We’ve long been doing a fine job covering the breaking news in R&D — if I do say so myself — but we needed to expand our horizons on industry coverage, increase the staff and go much, much deeper when the stories demanded it.
In a phrase: broader and deeper.
It’s safe to say, based on our daily web traffic, that you all seemed to like this idea. We’ve doubled the staff — thanks to a growing group of paid subscribers — ramped up the daily report and now publish a regular slate of in-depth articles. And traffic — those clicks you always read about — have gone up in volume too. Monthly sessions are up 43%, to close to 1.5 million. Unique readers are up 63%, to 874,480 in October, after setting a record of close to a million the month before. Page views are running at 3 million-plus a month. And the overall number of subscribers has surged to 124,000.
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
Australia’s Avance Clinical: no IND required and a 43.5% rebate on clinical spend for CGT biotechs
Avance Clinical is the specialist Australian CRO, with CGT accreditation, for international biotechs that leverages Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend.
Learn more about Avance ClinicReady here.
Contact us about your next study.
Download our Frost & Sullivan APAC CRO Report here.
The cell and gene therapies (CGT) sector offers unprecedented opportunities for patient disease management across virtually all therapeutic areas. However, finding the right accredited clinical teams to take a therapy through to the clinic and manage the regulatory process can be a major challenge for biotechs with a CGT product.
Ursula von der Leyen, President of the European Commission
As Americans were waking up for their Black Friday rituals, they were greeted with the news that a new mutation of the Covid-19 virus has appeared and been sequenced — after it caught an international flight to Hong Kong. And two of the leading Covid-19 vaccine developers promised delivery of a new vaccine ‘within 100 days’ if necessary.
The variant is now tagged as B.1.1.529.
Here’s what we know.
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
After a second look, Merck says that its big breakthrough on the Covid front doesn’t look so good.
The pharma giant updated its data on its oral antiviral molnupiravir on Friday, and said that its drug reduced the rate of hospitalization and death by 30% — a sharp plunge from the 50% rate reported at the beginning of October during their interim readout.
And the news sparked a sharp retreat on Merck’s shares, which fell 4% ahead of the bell on Friday.
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
The FDA has slapped a clinical hold on the early-stage program for one of Kura Oncology’s cancer drugs following a patient’s death in a clinical trial.
The biotech $KURA reported early Wednesday that the Phase Ib study of KO-539 for acute myeloid leukemia would be halted, suspending enrollment, while researchers and the FDA probed the death. Patients already on the drug can continue taking it.
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
Forget the migraine marketing brand wars. When it comes to patients, many can’t even name one despite substantial advertising efforts, according to a new study from Phreesia that concludes CGRP migraine drugmakers still need to work on brand recognition.
Almost half (47%) of the patients Phreesia surveyed couldn’t name one preventative migraine brand. The best performer was Topamax, a small molecule anticonvulsant that’s been around since 2004, which 26% of migraine patients could recall. Among the new CGRP brand names recognized, Amgen’s Aimovig ranked highest with 8% recall, while Eli Lilly’s Emgality and Biohaven’s Nurtec tied at 7% and Teva’s Ajovy was remembered by 3% of patients.
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
Emma Walmsley, GlaxoSmithKline CEO (Fang Zhe/Xinhua/Alamy Live News)
As activist investors champ at the bit for change at drug giant GlaxoSmithKline, the pharma giant has turned over many rocks to find an R&D success to present to its detractors. In NASH, a field strewn with failures, GSK hopes a new license deal can churn out a much-needed winner.
GSK will pay $120 million in upfront cash and $910 million in downstream milestones to develop and sell ARO-HSD, Arrowhead Pharmaceuticals’ RNA interference drug targeting fatty liver disease nonalcoholic steatohepatitis (NASH), the companies said Monday.
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
Amidst a push to ease pressure on the supply chain domestically, BD Biosciences will expand at the San Diego Reagent Innovation Center, as the property developer announced the company’s plans Monday.
The San Diego site will be at Torrey View, a 10-acre life sciences R&D campus that Breakthrough Properties is creating alongside Mitsui Fudosan America. It’s within the life sciences cluster of Del Mar Heights, which offers nearby housing for employees in biopharma.
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
Robert Califf (Pablo Martinez Monsivais, AP Images)
President Biden’s nominee to run the FDA was hit with some tepid criticism back in 2016 for being too cozy with the biopharma industry because some of the trials he ran had industry sponsors and some of the funding he took was from industry.
Nevertheless, Rob Califf sailed through his confirmation then, and his successor Scott Gottlieb showed that even closer ties to industry shouldn’t stop an effective leader from being FDA commissioner.
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
Most people know if they’re ‘Team Pfizer’ or ‘Team Moderna,’ but few know if they got the Comirnaty or Spikevax Covid-19 vaccine. Those are the brand names of Pfizer and Moderna vaccines, respectively, however they have yet to take hold with consumers, media or even medical professionals.
And there are others. Covid vaccine brand names also include AstraZeneca’s Vaxzevria, Novavax’s Nuvaxovid, and Sanofi and GlaxoSmithKline’s Vidprevtyn. J&J’s Janssen-developed Covid vaccine is the lone major holdout and is still yet to be named, if ever. In EMA filings approving its conditional use, the brand name is listed simply as ‘Covid-19 Vaccine Janssen.’
Unlock this story instantly and join 124,100+ biopharma pros reading Endpoints daily — and it’s free.
https://endpts.com/what-were-endpoints-readers-tuning-into-this-year-heres-a-look-at-our-15-most-popular-reports-of-the-year-so-far/
